{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:32:39Z","timestamp":1792503159051,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":111,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002507","name":"Kangwon National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2024IP0020-1"],"award-info":[{"award-number":["2024IP0020-1"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2022"],"award-info":[{"award-number":["2022"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1053\/j.seminhematol.2025.11.002","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:32:59Z","timestamp":1763692379000},"page":"350-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Trispecific T cell engagers in hematological malignancies: Advancing beyond bispecific antibodies"],"prefix":"10.1053","volume":"62","author":[{"given":"Kyung-Nam","family":"Koh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-5398","authenticated-orcid":false,"given":"Hyori","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2025.11.002_bib0001","series-title":"European Hematology Association Congress 2025. Acta Haematol","first-page":"600","article-title":"Highlights from the European Hematology Association Congress 2025","author":"Schmale","year":"2025"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.002_bib0002","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody theapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6382","key":"10.1053\/j.seminhematol.2025.11.002_bib0003","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.002_bib0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.002_bib0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.002_bib0007","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.002_bib0008","first-page":"418","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.002_bib0009","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.002_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115319","article-title":"From molecular precision to clinical practice: a comprehensive review of bispecific and trispecific antibodies in hematologic malignancies","volume":"26","author":"Amoozgar","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"41","key":"10.1053\/j.seminhematol.2025.11.002_bib0012","article-title":"Targeting dual immune checkpoints PD-L1 and HLA-G by trispecific T cell engager for treating heterogeneous lung cancer","volume":"11","author":"Lin","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0013","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: design, therapy, perspectives","volume":"12","author":"Sedykh","year":"2018","journal-title":"Drug Des Devel Ther,"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0014","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.002_bib0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2010.02.008","article-title":"The synapse and cytolytic machinery of cytotoxic T cells","volume":"22","author":"Jenkins","year":"2010","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.002_bib0016","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0017","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.11.002_bib0018","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.002_bib0019","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.002_bib0021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nri727","article-title":"The B7-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.002_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0023","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy: assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.002_bib0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/13543784.2025.2511180","article-title":"Clinical development of tri-specific antibodies for immune- oncology","volume":"34","author":"Cao","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.002_bib0026","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106781","article-title":"Improving the tumor selectivity of T cell engagers by logic-gated dual tumor-targeting","volume":"192","author":"Shen","year":"2023","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2115213","article-title":"Development of T-cell engagers selective for cells co- expressing two antigens","volume":"14","author":"Dicara","year":"2022","journal-title":"MAbs"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0029","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1158\/1538-7445.AM2025-7292","article-title":"A trispecific T-cell engager with immune checkpoint inhibitor targeting mesothelin for solid cancer","volume":"85","author":"Hu","year":"2025","journal-title":"Cancer Research"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0030","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2021-152160","article-title":"Preclinical assessment of CDR101 - a BCMAxCD3xPD-L1 trispecific antibody with superior anti-tumor efficacy","volume":"138","author":"Vrohlings","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.002_bib0031","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/imt-2023-0256","article-title":"A trispecific antibody induces potent tumordirected T-cell activation and antitumor activity by CD3\/CD28 coengagement","volume":"16","author":"Chen","year":"2024","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0032","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.002_bib0033","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against Tcell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0034","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"16","author":"Amash","year":"2024","journal-title":"MAbs"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0035","series-title":"the 66th ASH annual meeting. Blood","first-page":"3356","author":"An","year":"2024"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0036","series-title":"the 66th ASH annual meeting. Blood","first-page":"3381.2","volume":"144","author":"Xu","year":"2024"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0037","series-title":"2025 ASCO Annual Meeting. J Clin Oncol","first-page":"7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results","volume":"43","author":"van de","year":"2025"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0038","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-0716-4558-1_20","article-title":"Optimal structural designs of trispecific antibodies to enhance therapeutic efficacy in solid tumors and hematological malignancies","volume":"2930","author":"Qi","year":"2025","journal-title":"Meth Mol Biol"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.11.002_bib0039","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.7150\/thno.75037","article-title":"A Novel Her2\/VEGFR2\/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2570748","article-title":"Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody design","volume":"17","author":"Zhao","year":"2025","journal-title":"MAbs"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0041","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11684-021-0835-8","article-title":"Preclinical characterization and comparison between CD3\/CD19 bispecific and novel CD3\/CD19\/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia","volume":"16","author":"Wang","year":"2022","journal-title":"Front Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.002_bib0042","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1111\/bjh.19784","article-title":"A CD38\/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and\/or refractory to anti-CD38 monoclonal antibodies","volume":"205","author":"Zabaleta","year":"2024","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1053\/j.seminhematol.2025.11.002_bib0043","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0044","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.002_bib0045","first-page":"16","article-title":"Preclinical characterization of the anti-leukemia activity of the CD33\/CD16a\/NKG2D immune-modulating TriNKET(R) CC-96191","author":"Lunn-Halbert","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.002_bib0046","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0047","series-title":"the 66th ASH annual meeting. Blood","first-page":"1026","article-title":"First results of a phase 1, first-in-human, dose escalation study of ISB 2001, a BCMAxCD38xCD3 targeting trispecific antibody in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"144","author":"Quach","year":"2024"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.002_bib0048","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/13543784.2025.2511179","article-title":"Emerging GPRC5D-targeted therapies for multiple myeloma: a comprehensive review","volume":"34","author":"Pan","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.002_bib0049","doi-asserted-by":"crossref","first-page":"E222","DOI":"10.1002\/ajh.26988","article-title":"CD19-negative relapse in adult patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis","volume":"98","author":"Horst","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.002_bib0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-Cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0051","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.002_bib0052","doi-asserted-by":"crossref","first-page":"432","DOI":"10.37349\/etat.2024.00227","article-title":"Tri-specific killer engager: unleashing multisynergic power against cancer","volume":"5","author":"Winidmanokul","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0053","article-title":"Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.002_bib0054","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1472195","article-title":"Dual-targeting triplebody 33-16-123 (SPM-2) mediates ef fective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells","volume":"7","author":"Braciak","year":"2018","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.002_bib0055","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.002_bib0056","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.1711540304","article-title":"Activation and differentiation antigen expression in B-cell non-Hodgkin\u2019s lymphoma","volume":"154","author":"Salter","year":"1988","journal-title":"J Pathol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0057","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"Geraud","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.002_bib0059","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7150\/thno.81494","article-title":"When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy","volume":"13","author":"Tapia-Galisteo","year":"2023","journal-title":"Theranostics"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.002_bib0060","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cancers17020282","article-title":"Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies","volume":"17","author":"Bangolo","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"399","key":"10.1053\/j.seminhematol.2025.11.002_bib0061","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIIIdirected CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.002_bib0062","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cancers12051075","article-title":"Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6230","key":"10.1053\/j.seminhematol.2025.11.002_bib0063","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.002_bib0064","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1084\/jem.20151159","article-title":"T cell metabolism drives immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J Exp Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0065","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2338558","article-title":"Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-beta and PD-L1 enhances antitumor responses","volume":"13","author":"Tapia-Galisteo","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0066","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025029215","article-title":"An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden","author":"Meermeier","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.002_bib0067","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"issue":"6537","key":"10.1053\/j.seminhematol.2025.11.002_bib0068","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.002_bib0069","first-page":"496","article-title":"Targeted therapy: resistance and re-sensitization","volume":"34","author":"Chen","year":"2015","journal-title":"Chin J Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.002_bib0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.002_bib0071","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/2767-9764.CRC-23-0434","article-title":"Ex Vivo efficacy of SAR442257 Anti-CD38 trispecific T-cell en gager in multiple myeloma relapsed after daratumumab and BCMAtargeted therapies","volume":"4","author":"Keller","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1053\/j.seminhematol.2025.11.002_bib0072","article-title":"Mechanistic insights into resistance mechanisms to T cell engagers","volume":"16","author":"Cao","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0073","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.002_bib0074","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/hematology.2020000110","article-title":"Bispecifics, trispecifics, and other novel immune treatments in myeloma","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.002_bib0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010140","article-title":"Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer","volume":"13","author":"Sun","year":"2025","journal-title":"J Immunother Cancer"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:54:04Z","timestamp":1777442044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0037196325000514"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trispecific T cell engagers in hematological malignancies: Advancing beyond bispecific antibodies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}